PubRank

R Kettler

Author PubWeight™ 34.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Selective induction by nerve growth factor of tyrosine hydroxylase and dopamine- -hydroxylase in the rat superior cervical ganglia. Proc Natl Acad Sci U S A 1971 1.96
2 In vivo enhancement of tyrosine hydroxylation in rat striatum by tetrahydrobiopterin. Nature 1974 1.51
3 Comparative studies on the effect of the nerve growth factor on sympathetic ganglia and adrenal medulla in newborn rats. Brain Res 1972 1.44
4 PDPH in obstetric anesthesia: comparison of 24-gauge Sprotte and 25-gauge Quincke needles and effect of subarachnoid administration of fentanyl. Reg Anesth 1993 1.39
5 Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 1997 1.31
6 Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 1992 1.30
7 Functional analysis of an olfactory receptor in Drosophila melanogaster. Proc Natl Acad Sci U S A 2001 1.28
8 Time course of the development of enzymes involved in the synthesis of norepinephrine in the superior cervical ganglion of the rat from birth to adult life. Brain Res 1972 1.02
9 Nicotinamide is a brain constituent with benzodiazepine-like actions. Nature 1979 1.00
10 Some basic aspects of reversible inhibitors of monoamine oxidase-A. Acta Psychiatr Scand Suppl 1990 1.00
11 [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice]. Psychiatr Prax 1989 0.98
12 Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. Adv Neurol 1990 0.96
13 Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989 0.95
14 From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl 1990 0.94
15 Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991 0.93
16 Local anesthetic myotoxicity: a case and review. Anesthesiology 1994 0.92
17 Nerve growth factor and preganglionic cholinergic nerves; their relative importance to the development of the terminal adrenergic neuron. Brain Res 1972 0.91
18 Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol 1996 0.89
19 Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. Br J Clin Pharmacol 1994 0.89
20 The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia 1984 0.89
21 Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol 1985 0.86
22 Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 1990 0.86
23 Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Naunyn Schmiedebergs Arch Pharmacol 1987 0.85
24 Neurally mediated control of enzymes involved in the synthesis of norepinephrine; are they regulated as an operational unit? Naunyn Schmiedebergs Arch Pharmakol 1971 0.85
25 Success rates in producing sympathetic blockade by paratracheal injection. Clin J Pain 1994 0.85
26 Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl 1989 0.84
27 Pharmacology of moclobemide. Clin Neuropharmacol 1993 0.84
28 Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 1987 0.82
29 Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology (Berl) 1992 0.82
30 Investigation of a correlation between monoamine oxidase B and catechol-O-methyltransferase activity in human blood cells. Eur J Pharm Sci 2000 0.81
31 Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm Suppl 1990 0.81
32 Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl) 1992 0.80
33 L-cycloserine: behavioural and biochemical effects after single and repeated administration to mice, rats and cats. Neuropharmacology 1986 0.78
34 Species differences in changes of heart monoamine oxidase activities with age. J Neural Transm Suppl 1994 0.78
35 Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. J Neural Transm Suppl 1994 0.78
36 Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm Suppl 1990 0.77
37 Current density and conductivity dependent electroporation of Escherichia coli C600. Prog Biophys Mol Biol 2012 0.77
38 Pre-clinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry Suppl 1989 0.75
39 Reversible, enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacol Res Commun 1988 0.75
40 Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme. Pharmacol Res Commun 1988 0.75
41 Characteristics of procarbazine as an inhibitor in-vitro of rat semicarbazide-sensitive amine oxidase. J Pharm Pharmacol 1992 0.75
42 Radioautographic evidence that the GABAA receptor antagonist SR 95531 is a substrate inhibitor of MAO-A in the rat and human locus coeruleus. Eur J Neurosci 1994 0.75
43 Monitoring induced gene expression of single cells in a multilayer microchip. Anal Bioanal Chem 2011 0.75
44 [Psychotherapy for children and adolescents at the Institute for Psychogenic Diseases of the National Health Insurance in Berlin]. Prax Kinderpsychol Kinderpsychiatr 1977 0.75
45 Uptake, metabolism and subcellular localization of MPTP and MPP+ in blood platelets. Clin Neuropharmacol 1986 0.75
46 The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain. J Neural Transm Park Dis Dement Sect 1990 0.75
47 Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide. Acta Psychiatr Scand Suppl 1990 0.75
48 Benzodiazepine receptor: localization by photoaffinity labeling and isolation of a possible endogenous ligand. Adv Biochem Psychopharmacol 1980 0.75
49 Absence of degeneration of adrenergic neurons after prolonged treatment with debrisoquin. J Pharmacol Exp Ther 1974 0.75
50 Absence of degeneration of adrenergic neurones after prolonged treatment of newborn rats with debrisoquin. Acta Pharmacol Toxicol (Copenh) 1975 0.75
51 Conversion of the neurotoxic precursor 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine into its pyridinium metabolite by human platelet monoamine oxidase type B. Neurosci Lett 1985 0.75
52 Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor. Mod Probl Pharmacopsychiatry 1983 0.75
53 Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Br J Clin Pharmacol 1997 0.75
54 Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats. Psychopharmacology (Berl) 1992 0.75
55 The cardiovascular effects of the antihypertensive drug debrisoquin: A contribution to the pharmacology of chronic treatment. III. Absence of adrenergic degeneration after 8-week administration to dogs. J Pharmacol Exp Ther 1978 0.75
56 Resolution, EPC-syntheses, absolute stereochemistry, and pharmacology of the (S)-(+)- and (R)-(-)-isomers of the MAO-A inhibitor tetrindole hydrochloride. Arch Pharm (Weinheim) 1996 0.75
57 Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Adv Neurol 1987 0.75